logo

For the Inventor, By the Inventor

Wrexham, United Kingdom

Ipsen Biopharm Limited


USPTO Granted Patents = 41


Trademarks = 12

Forward Citations = 214

Loading Chart...
Loading Chart...

76 inventors (with patents filed for the assignee):

goldMedal Daryl C Drummond (13 out of 36 patents)

silverMedal Dmitri B Kirpotin (11 out of 45 patents)

bronzeMedal Jonathan Basil Fitzgerald (9 out of 19 patents)

4.  Keelung Hong (7 out of 51 patents)

5.  Victor Mandla Moyo (6 out of 43 patents)

6.  Eliel Bayever (5 out of 9 patents)

7.  Navreet Dhindsa (4 out of 8 patents)

8.  Peter Laivins (4 out of 8 patents)

9.  Clet Niyikiza (4 out of 37 patents)

10.  Jaeyeon Kim (4 out of 8 patents)

11.  Mary White (4 out of 5 patents)

12.  Julie Partington (4 out of 4 patents)

13.  Paul Webb (4 out of 14 patents)

14.  Sarah F Blanchette (3 out of 4 patents)

15.  Charles Noble (3 out of 21 patents)


Core Competencies:
Chimeric Neurotoxins
Pancreatic Cancer Treatment
Liquid Neurotoxin Formulation
Combination Cancer Therapy
Botulinum Neurotoxins
Liposomal Drug Delivery
Clostridial Neurotoxin Production
Stabilizing Pharmaceutical Compositions
Bone Cancer Allodynia Suppression
Nanoliposomal Irinotecan
Recombinant Clostridium Botulinum
Quantification of Botulinum Toxin

41 patents:

1. 12421284 - Chimeric neurotoxins (2025-09-23),
2. 12364691 - Methods for treating pancreatic cancer using combination therapies (2025-07-22),
3. 12285468 - Liquid neurotoxin formulation stabilized with tryptophan or tyrosine (2025-04-29),
4. 12060553 - Evolution of BoNT peptidases (2024-08-13),
5. 12059497 - Stabilizing camptothecin pharmaceutical compositions (2024-08-13),
6. 11975055 - Suppression of bone cancer-induced allodynia (2024-05-07),
7. 11844795 - Combination therapy for cancer treatment (2023-12-19),
8. 11634460 - Non-neuronal snare-cleaving botulinum neurotoxins (2023-04-25),
9. 11534394 - Pharmaceutical composition containing botulinum neurotoxin (2022-12-27),
10. 11453903 - Production of activated clostridial neurotoxins (2022-09-27),
11. 11434265 - Chimeric neurotoxins (2022-09-06),
12. 11369597 - Methods for treating pancreatic cancer using combination therapies (2022-06-28),
13. 11344552 - Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin (2022-05-31),
14. 11318131 - Nanoliposomal irinotecan for use in treating small cell lung cancer (2022-05-03),
15. 11193931 - Cellular vamp cleavage assay (2021-12-07),
Ipsen Biopharm Limited is a global biotechnology company specializing in developing and commercializing innovative medicines in oncology, neuroscience, and rare diseases. With a strong focus on research and development, Ipsen Biopharm is committed to improving patients' lives and providing better treatment options. Their diverse portfolio of products and therapies caters to various therapeutic areas and has a significant impact on patients and healthcare providers worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

41 Patents

#1 in Wrexham

#421 in United Kingdom

#16,217 in the World

...
Wrexham, United Kingdom

Ipsen Biopharm Limited

Forward Citations = 214

76 inventors:

goldMedal Daryl C Drummond (13 out of 36 patents)

silverMedal Dmitri B Kirpotin (11 out of 45 patents)

bronzeMedal Jonathan Basil Fitzgerald (9 out of 19 patents)

4.  Keelung Hong (7 out of 51 patents)

5.  Victor Mandla Moyo (6 out of 43 patents)

Please report any incorrect information to support@idiyas.com
Loading…